USD 133.8 Billion
Monoclonal Antibody Therapy Market Size, Share, Growth Analysis, By Type(Murine Antibodies, Chimeric Antibodies, Humanised Antibodies and Fully Human Antibodies), By Application(Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Conditions and Others.), By Region - Industry Forecast 2024-2031
Report ID:
SQMIG35A2527 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|Tables:
64
|Figures:
75
Monoclonal Antibody Therapy Market Insights
Monoclonal Antibody Therapy Market size was valued at USD 143.56 Billion in 2022 and is poised to grow from USD 154.05 Billion in 2023 to USD 270.68 Billion by 2031, at a CAGR of 7.3% during the forecast period (2023-2030).
One of the primary drivers of the global monoclonal antibody therapy market is the increasing prevalence of chronic diseases, such as cancer, autoimmune disorders, and cardiovascular diseases. Monoclonal antibody therapies have shown promising results in the treatment of these conditions, leading to their growing adoption. Additionally, the aging population and the rise in lifestyle-related diseases have further contributed to the market growth. Technological advancements have enabled the production of highly specific and effective antibodies, increasing their therapeutic efficacy. Additionally, the growing focus on personalised medicine and targeted therapies has further fueled the demand for monoclonal antibody therapies.
US Monoclonal Antibody Therapy Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2023-2030
Global Market Size
Largest Segment
Humanized antibodies
Fastest Growth
Humanized antibodies
Growth Rate
7.3% CAGR
Global Monoclonal Antibody Therapy Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Monoclonal Antibody Therapy Market Segmental Analysis
The global monoclonal antibody therapy market is segmented based on type, application, and region. Based on type, the market can be segmented into Murine Antibodies, Chimeric Antibodies, Humanised Antibodies, and Fully Human Antibodies. Based on application, the market is segmented into Oncology, Autoimmune Diseases, Infectious Diseases, Inflammatory Conditions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Monoclonal Antibody Therapy Market Analysis by Type
In the global monoclonal antibody therapy market, the most dominant type among Murine Antibodies, Chimeric Antibodies, Humanised Antibodies, and Fully Human Antibodies is Humanised Antibodies. This dominant segment has gained significant prominence in the market due to their reduced immunogenicity and improved therapeutic efficacy compared to Murine Antibodies.
On the other hand, the fastest-growing type in the global Monoclonal Antibody Therapy market is Fully Human Antibodies. Fully human antibodies are derived from human sources and exhibit high specificity and affinity, making them highly effective in targeting specific antigens. These antibodies have shown great potential in treating various diseases and have gained traction in the pharmaceutical industry.
Monoclonal Antibody Therapy Market Analysis by Application
In the global monoclonal antibody therapy market, the most dominant application is Oncology. Monoclonal antibody therapies have revolutionised cancer treatment by targeting specific cancer cells or molecules involved in cancer growth. The effectiveness of these therapies, coupled with the increasing prevalence of cancer worldwide, has made Oncology the dominant application in the market.
The fastest-growing application in the global monoclonal antibody therapy market is autoimmune diseases. Monoclonal antibody therapies have shown significant success in treating autoimmune diseases by modulating the immune system and targeting specific components responsible for the disease. The rising incidence of autoimmune diseases and the need for more effective treatment options have fueled the growth of this application in the market.
Global Monoclonal Antibody Therapy Market By Type
To get detailed analysis on other segments, Request For Free Sample Report
Monoclonal Antibody Therapy Market Regional Insights
In the global monoclonal antibody therapy market, the most dominant region is North America. North America has a strong presence in the market due to factors such as well-established healthcare infrastructure, advanced research and development facilities, and a high adoption rate of monoclonal antibody therapies. The region is home to several prominent pharmaceutical companies and biotechnology firms that are actively involved in the development and commercialization of monoclonal antibody therapies. Additionally, favourable reimbursement policies and government support for innovative therapies contribute to the dominance of North America in the market.
Regarding the fastest-growing region, Asia Pacific is witnessing significant growth in the global Monoclonal Antibody Therapy market. The region is experiencing an increasing prevalence of chronic diseases, a rising geriatric population, and improving healthcare infrastructure. These factors, along with the growing awareness and affordability of advanced therapies, have led to a surge in the demand for monoclonal antibody therapies in the Asia Pacific region. Furthermore, the presence of a large patient pool, expanding pharmaceutical industry, and increasing investments in research and development activities contribute to the rapid growth of the market in Asia Pacific.
Global Monoclonal Antibody Therapy Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Monoclonal Antibody Therapy Market Dynamics
Monoclonal Antibody Therapy Market Drivers
Advancements in Biotechnology and Genetic Engineering
- Significant progress in biotechnology and genetic engineering has played a pivotal role in the development of advanced monoclonal antibody therapies. These advancements have facilitated the engineering of antibodies with improved specificity, efficacy, and reduced side effects. Through techniques such as genetic manipulation, researchers can optimise monoclonal antibodies for specific targets, enhancing their therapeutic potential. These breakthroughs have broadened the range of applications for monoclonal antibody therapies and increased their success rates.
Monoclonal Antibody Therapy Market Restraints
Potential Side Effects and Safety Concerns
- Like any medical intervention, monoclonal antibody therapies carry the potential for side effects and safety concerns. Some patients may experience reactions related to the administration of the therapy, such as infusion-related reactions. Additionally, there is a possibility of immunogenicity, where the patient's immune system may mount an immune response against the therapy. Off-target effects, where the therapy may interact with unintended targets in the body, can also occur. It is crucial to closely monitor and address these safety concerns to ensure patient well-being, maintain confidence in the therapy, and adhere to regulatory standards. Continuous monitoring, robust safety assessment, and clear communication of potential risks are vital in managing these concerns effectively.
Request Free Customization of this report to help us to meet your business objectives.
Monoclonal Antibody Therapy Market Competitive Landscape
The global monoclonal antibody therapy market is highly competitive and dynamic, characterised by the presence of numerous pharmaceutical and biotechnology companies. Monoclonal antibody therapy has gained significant traction in the healthcare industry due to its targeted approach and effectiveness in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. The competitive landscape of this market is shaped by factors such as research and development activities, product portfolio, strategic collaborations, and regulatory approvals.
Monoclonal Antibody Therapy Market Top Player’s Company Profiles
- Roche Holding AG (Switzerland)
- Johnson & Johnson (US)
- Novartis International AG (Switzerland)
- Pfizer Inc. (US)
- Merck & Co., Inc. (US)
- Amgen Inc. (US)
- AstraZeneca PLC (UK)
- Bristol Myers Squibb Company (US)
- AbbVie Inc. (US)
- Eli Lilly and Company (US)
- Sanofi S.A. (France)
- GlaxoSmithKline plc (UK)
- Takeda Pharmaceutical Company Limited (Japan)
- Biogen Inc. (US)
- Regeneron Pharmaceuticals, Inc. (US)
- Moderna, Inc. (US)
- BioNTech SE (Germany)
- Alexion Pharmaceuticals, Inc. (US)
- Gilead Sciences, Inc. (US)
- CSL Limited (Australia)
Monoclonal Antibody Therapy Market Recent Developments
- In June 2023, Bristol-Myers Squibb Company announced the approval of its new monoclonal antibody therapy, Brexucabtagene autoleucel (JCAR015), for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies. Brexucabtagene autoleucel is a type of CAR T-cell therapy, which is a type of immunotherapy that uses a patient's own immune cells to fight cancer. In Brexucabtagene autoleucel, a patient's white blood cells are removed from their body, genetically modified to express a chimeric antigen receptor (CAR), and then infused back into the patient. The CAR helps the white blood cells to recognize and kill cancer cells.
- In May 2023, Eli Lilly and Company announced the approval of its new monoclonal antibody therapy, Taltz (ixekizumab), for the treatment of adults with moderate to severe plaque psoriasis. Taltz is a human monoclonal antibody that works by blocking the activity of a protein called interleukin-17A (IL-17A). IL-17A is involved in the inflammatory response that causes psoriasis, and by blocking its activity, Taltz helps to reduce inflammation and improve skin lesions.
- In April 2023, Genentech (Roche) announced the approval of its new monoclonal antibody therapy, Ocrevus (ocrelizumab), for the treatment of adults with relapsing multiple sclerosis. Ocrevus is a human monoclonal antibody that works by targeting B cells, a type of white blood cell that plays a role in the immune system. By targeting B cells, Ocrevus helps to reduce inflammation and slow the progression of multiple sclerosis.
- In March 2023, Johnson & Johnson announced the approval of its new monoclonal antibody therapy, Tremfya (guselkumab), for the treatment of adults with moderate to severe plaque psoriasis. Tremfya is a human monoclonal antibody that works by blocking the activity of a protein called interleukin-23 (IL-23). IL-23 is involved in the inflammatory response that causes psoriasis, and by blocking its activity, Tremfya helps to reduce inflammation and improve skin lesions.
- In February 2023, Novartis AG announced the approval of its new monoclonal antibody therapy, Kymriah (tisagenlecleucel), for the treatment of children and young adults with B-cell acute lymphoblastic leukaemia (ALL) that is refractory or has relapsed after two or more prior therapies. Kymriah is a type of CAR T-cell therapy, which is a type of immunotherapy that uses a patient's own immune cells to fight cancer. In Kymriah, a patient's white blood cells are removed from their body, genetically modified to express a chimeric antigen receptor (CAR), and then infused back into the patient. The CAR helps the white blood cells to recognize and kill cancer cells.
Monoclonal Antibody Therapy Key Market Trends
- Increasing Adoption and Development of Personalised and Targeted Therapies: Monoclonal antibody therapies have gained significant momentum in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Personalised medicine approaches, such as companion diagnostics, genetic profiling, and biomarker identification, are being integrated into the development and prescription of monoclonal antibody therapies. This trend allows for a more precise and tailored treatment approach, maximising therapeutic efficacy while minimising adverse effects.
Monoclonal Antibody Therapy Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to the global monoclonal antibody therapy market analysis, the rising prevalence of chronic diseases and the increasing demand for targeted and personalised therapies are prominent drivers. Monoclonal antibody therapy has emerged as a promising treatment option, providing highly specific and effective therapies for various medical conditions. One of the major drivers fueling the growth of the global monoclonal antibody therapy market is the increasing incidence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases. Monoclonal antibody therapy offers targeted treatment by specifically binding to disease-specific antigens, thereby reducing off-target effects and enhancing therapeutic outcomes. The rising geriatric population and the associated increase in age-related diseases further contribute to the market growth. Pharmaceutical companies and research institutes are investing extensively in research and development activities to discover and develop innovative monoclonal antibodies with enhanced efficacy and fewer side effects. This trend is expected to drive market growth in the coming years, as new therapeutic options become available. However, the market also faces challenges that need to be addressed. High treatment costs associated with monoclonal antibody therapies pose a significant barrier to their widespread adoption, particularly in developing regions. Additionally, stringent regulatory requirements and the lengthy and expensive drug approval process can hinder market growth.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 143.56 Billion |
| Market size value in 2031 | USD 270.68 Billion |
| Growth Rate | 7.3% |
| Base year | 2023 |
| Forecast period | 2023-2030 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Monoclonal Antibody Therapy Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Monoclonal Antibody Therapy Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Monoclonal Antibody Therapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Monoclonal Antibody Therapy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Monoclonal Antibody Therapy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Monoclonal Antibody Therapy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
